The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Renal Cell Carcinoma: A Review
Open accessAbstract
Importance: Renal cell carcinoma (RCC) is a common malignancy, with an estimated 434 840 incident cases worldwide in 2022. In the US, it is the sixth most common cancer among males and ninth among females. Observations: Clear cell RCC is the most common histologic subtype (75%-80% of cases) and is characterized by inactivation of the von Hippel Lindau (VHL) tumor suppressor gene. Many patients (37%-61%) are diagnosed with RCC incidentally on an abdominal imaging study such as ultrasound or computed tomographic scan, and 70% of patients have stage I RCC at diagnosis. Although its incidence has increased approximately 1% per year from 2015 through 2019, the mortality rate of RCC has declined about 2% per year in the US from 2016 through 2020. Patients with a solid renal mass or complex cystic renal mass should be referred to urology. Treatment options for RCC confined to the kidney include surgical resection with partial or radical nephrectomy, ablative techniques (eg, cryoablation, radiofrequency ablation, radiation), or active surveillance for some patients (especially those with renal masses <2 cm). For patients with renal masses less than 4 cm in size (48% of patients), partial nephrectomy can result in a 5-year cancer-specific survival of more than 94%. For advanced or metastatic RCC, combinations of immune checkpoint inhibitors or the combination of immune checkpoint inhibitors with tyrosine kinase inhibitors are associated with tumor response of 42% to 71%, with a median overall survival of 46 to 56 months. Conclusions and Relevance: RCC is a common malignancy that is often diagnosed incidentally on an abdominal imaging study. Seventy percent of patients are diagnosed with stage I RCC and 11% of patients with stage IV. First-line treatments for early-stage RCC are partial or radical nephrectomy, which can result in 5-year cancer-specific survival of more than 94%, ablative techniques, or active surveillance. New treatment options for patients with metastatic RCC include immune checkpoint inhibitors and tyrosine kinase inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Self-citationNivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816714 · Cited by 3,403
Heng, D. Y. C., Xie, W., Regan, M. M., Warren, M. A., Golshayan, A. R., Sahi, C., Eigl, B. J., Ruether, J. D., Cheng, T., North, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4809 · Cited by 2,133
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Choueiri, T. K., Powles, T., Burotto, M., Escudier, B., Bourlon, M. T., Zurawski, B., Oyervides Juárez, V. M., Hsieh, J. J., Basso, U., Shah, A. Y., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2026982 · Cited by 1,791
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Motzer, R., Alekseev, B., Rha, S.-Y., Porta, C., Eto, M., Powles, T., Grünwald, V., Hutson, T. E., Kopyltsov, E., Méndez-Vidal, M. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035716 · Cited by 1,766
Epidemiology of Renal Cell Carcinoma
Capitanio, U., Bensalah, K., Bex, A., Boorjian, S. A., Bray, F., Coleman, J., Gore, J. L., Sun, M., Wood, C., & Russo, P. (2019) · European Urology · doi:10.1016/j.eururo.2018.08.036 · Cited by 1,618
Huang, W. C., Levey, A. S., Serio, A. M., Snyder, M., Vickers, A. J., Raj, G. V., Scardino, P. T., & Russo, P. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70803-8 · Cited by 1,613
Research works printed but not linked: 28
- Jayson, 1998, Increased incidence of serendipitously discovered renal cell carcinoma., Urology, 51, 203, 10.1016/S0090-4295(97)00506-2 · doi:10.1016/s0090-4295(97)00506-2
- Cheung, 2016, Cancer incidence and mortality in chronic dialysis population: a multicenter cohort study., Am J Nephrol, 43, 153, 10.1159/000445362 · doi:10.1159/000445362
- Henschler, 1995, Increased incidence of renal cell tumors in a cohort of cardboard workers exposed to trichloroethene., Arch Toxicol, 69, 291, 10.1007/s002040050173 · doi:10.1007/s002040050173
- Skinner, 1971, Diagnosis and management of renal cell carcinoma: a clinical and pathologic study of 309 cases., Cancer, 28, 1165, 10.1002/1097-0142(1971)28:5<1165::AID-CNCR2820280513>3.0.CO;2-G · doi:10.1002/1097-0142(1971)28:5<1165::aid-cncr2820280513>3.0.co;2-g
- Takeuchi, 2021, Cancer prevalence and risk stratification in adults presenting with hematuria: a population-based cohort study., Mayo Clin Proc Innov Qual Outcomes, 5, 308, 10.1016/j.mayocpiqo.2020.12.001 · doi:10.1016/j.mayocpiqo.2020.12.001
- Loughlin, 2023, The great masquerader’s new wardrobe in the modern era: the paraneoplastic manifestations of renal cancer., Urol Clin North Am, 50, 305, 10.1016/j.ucl.2023.01.005 · doi:10.1016/j.ucl.2023.01.005
- Moldovan, 2023, Incidence and clinical relevance of paraneoplastic syndromes in patients with renal cell carcinoma., Urol Oncol, 41, 392.e11, 10.1016/j.urolonc.2023.06.015 · doi:10.1016/j.urolonc.2023.06.015
- Hegemann, 2018, Rare and changeable as a chameleon: paraneoplastic syndromes in renal cell carcinoma., World J Urol, 36, 849, 10.1007/s00345-018-2215-9 · doi:10.1007/s00345-018-2215-9
- Herts, 2018, Management of the incidental renal mass on CT: a white paper of the ACR Incidental Findings Committee., J Am Coll Radiol, 15, 264, 10.1016/j.jacr.2017.04.028 · doi:10.1016/j.jacr.2017.04.028
- Patel, 2019, Clinical stage migration and survival for renal cell carcinoma in the United States., Eur Urol Oncol, 2, 343, 10.1016/j.euo.2018.08.023 · doi:10.1016/j.euo.2018.08.023
- Ficarra, 2002, Prognostic factors in patients with renal cell carcinoma: retrospective analysis of 675 cases., Eur Urol, 41, 190, 10.1016/S0302-2838(01)00027-6 · doi:10.1016/s0302-2838(01)00027-6
- Dagher, 2017, Clear cell renal cell carcinoma: validation of World Health Organization/International Society of Urological Pathology grading., Histopathology, 71, 918, 10.1111/his.13311 · doi:10.1111/his.13311
- Johnson, 2015, Preoperatively misclassified, surgically removed benign renal masses: a systematic review of surgical series and United States population level burden estimate., J Urol, 193, 30, 10.1016/j.juro.2014.07.102 · doi:10.1016/j.juro.2014.07.102
- Rais-Bahrami, 2009, Incidentally discovered renal masses: oncological and perioperative outcomes in patients with delayed surgical intervention., BJU Int, 103, 1355, 10.1111/j.1464-410X.2008.08242.x · doi:10.1111/j.1464-410x.2008.08242.x
- Cheung, 2023, A matched analysis of active surveillance versus nephrectomy for T1a small renal masses., Eur Urol Oncol, 6, 535, 10.1016/j.euo.2023.01.008 · doi:10.1016/j.euo.2023.01.008
- Ozambela, 2020, Contemporary trends in percutaneous renal mass biopsy utilization in the United States., Urol Oncol, 38, 835, 10.1016/j.urolonc.2020.07.022 · doi:10.1016/j.urolonc.2020.07.022
- Srivastava, 2021, Renal mass biopsy: a strategy to reduce associated costs and morbidity when managing localized renal masses., Urol Oncol, 39, 790.e9, 10.1016/j.urolonc.2021.06.015 · doi:10.1016/j.urolonc.2021.06.015
- Asselin, 2020, Does renal tumor biopsies for small renal carcinoma increase the risk of upstaging on final surgery pathology report and the risk of recurrence?, Urol Oncol, 38, 798.e9, 10.1016/j.urolonc.2020.06.001 · doi:10.1016/j.urolonc.2020.06.001
- Pierorazio, 2016, Management of renal masses and localized renal cancer: systematic review and meta-analysis., J Urol, 196, 989, 10.1016/j.juro.2016.04.081 · doi:10.1016/j.juro.2016.04.081
- Neves, 1987, Surgical treatment of renal cancer with vena cava extension., Br J Urol, 59, 390, 10.1111/j.1464-410X.1987.tb04832.x · doi:10.1111/j.1464-410x.1987.tb04832.x
- Ciancio, 2010, Long-term survival in patients undergoing radical nephrectomy and inferior vena cava thrombectomy: single-center experience., Eur Urol, 57, 667, 10.1016/j.eururo.2009.06.009 · doi:10.1016/j.eururo.2009.06.009
- Pecoraro, 2019, Cryoablation predisposes to higher cancer specific mortality relative to partial nephrectomy in patients with nonmetastatic pT1b kidney cancer., J Urol, 202, 1120, 10.1097/JU.0000000000000460 · doi:10.1097/ju.0000000000000460
- Motzer, 2024, Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: results from part B of the randomized, phase 3 CheckMate 914 trial., J Clin Oncol, 42, LBA358, 10.1200/JCO.2024.42.4_suppl.LBA358 · doi:10.1200/jco.2024.42.4_suppl.lba358
- Wang, 2023, Burden of surgeries and surgical complications in patients with Von Hippel Lindau (VHL) disease before and after treatment with belzutifan., J Clin Oncol, 41, 733, 10.1200/JCO.2023.41.6_suppl.733 · doi:10.1200/jco.2023.41.6_suppl.733
- Appleman, 2024, Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease after metastasectomy: ECOG-ACRIN E2810., J Clin Oncol, 42, 2061, 10.1200/JCO.23.01544 · doi:10.1200/jco.23.01544
- Tannir, 2024, Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): long-term follow-up data from the phase 3 CheckMate 214 trial., J Clin Oncol, 42, 363, 10.1200/JCO.2024.42.4_suppl.363 · doi:10.1200/jco.2024.42.4_suppl.363
- Osterman, 2020, Trends in initial systemic therapy for elderly patients with metastatic clear cell renal cell carcinoma., Kidney Cancer, 4, 131, 10.3233/KCA-200089 · doi:10.3233/kca-200089
- Strohbehn, 2021, Registration trials in countries without access to US standards of care—pitfalls of interpretation., Nat Rev Clin Oncol, 18, 395, 10.1038/s41571-021-00506-z · doi:10.1038/s41571-021-00506-z
Cited by
Cancer treatment and survivorship statistics, 2025
Wagle, N. S., Nogueira, L., Devasia, T. P., Mariotto, A. B., Yabroff, K. R., Islami, F., Jemal, A., Alteri, R., Ganz, P. A., & Siegel, R. L. (2025) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.70011 · Cited by 261
Ji, X., Yun, Y., Zhu, Z., Wu, T., Ruan, M., Fan, Y., & Zhang, Q. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04266-7
Metadata
- Authors
- Rose, T. L., & Kim, W. Y.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2024-09-24
- Volume
- 332
- Issue
- 12
- Pages
- 1001
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4401948805
- Cited by
- 374
- References
- 56
- FWCI
- 95.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Renal Cell Carcinoma: A Review. https://app.cochat.ai/papers/10.1001/jama.2024.12848
- The paper
- Rose, T. L., & Kim, W. Y. (2024). Renal Cell Carcinoma: A Review. JAMA. https://doi.org/10.1001/jama.2024.12848
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.